Biofrontera Inc.·4

Mar 6, 9:33 PM ET

Weber Kevin Daniel 4

4 · Biofrontera Inc. · Filed Mar 6, 2026

Research Summary

AI-generated summary of this filing

Updated

Biofrontera (BFRI) Director Kevin D. Weber Receives 20,000-Share Award

What Happened

  • Kevin Daniel Weber, a director of Biofrontera Inc. (BFRI), received a derivative award on March 4, 2026 covering 20,000 shares. The Form 4 reports an acquisition price of $0.00 and a reported value of $0 for the award (derivative security).

Key Details

  • Transaction date: 2026-03-04; Report filed: 2026-03-06.
  • Reported terms: 20,000 derivative shares acquired @ $0.00; total reported value $0.
  • Vesting: The award vests in twelve equal monthly installments beginning April 4, 2026 (Footnote F1).
  • Notes: The filing states “options with different terms are not included” (Footnote F2).
  • Shares owned after transaction: Not specified in the provided filing.

Context

  • This was a grant/award of a derivative security (an option-type award per the footnote). Such awards are typically part of director compensation and are not the same as an open-market purchase or sale. The filing does not indicate any immediate sale or cashless exercise.

Insider Transaction Report

Form 4
Period: 2026-03-04
Transactions
  • Award

    Employee stock option (right to buy)

    [F1][F2]
    2026-03-04+20,00020,000 total
    Exercise: $0.90Exp: 2036-03-04Common Stock (20,000 underlying)
Footnotes (2)
  • [F1]The option vests in twelve equal monthly installments beginning on April 4, 2026.
  • [F2]Options with different terms are not included.
Signature
/s/ Daniel Hakansson, Attorney-in-fact for Kevin D. Weber|2026-03-06

Documents

1 file
  • 4
    ownership.xmlPrimary

    4